ABL Diagnostics Targets a Growth of +76.5% by 2026
The molecular diagnostics company announced on Monday a major acceleration in its growth, driven by the technological integration completed in 2025 and the full deployment of its exclusive distribution agreements. This leap of +76.5% represents a historic scale-up according to the management.
Acceleration in Kits and Reagents, Driven by the UltraGene Range
The kits and reagents segment crosses a new threshold with a target growth of 82.9% to reach €5.8M. This dynamic is based on two distinct drivers. The UltraGene range (syndromic qPCR tests, from the acquisition of Fast Track Diagnostics) shows an exceptional growth of 353.5% to €1.6M. The company's historic activity in HIV resistance testing, a recurring foundation of the company, maintains a robust momentum with a projected increase of 132.0% to €3.9M.
These two product lines embody the strategy of technological integration initiated the previous year and confirm the viability of the company's business model positioned as a global player in in vitro diagnostics.
Distribution Agreements Account for More Than Half of the Growth
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The services and other segment sees its revenues nearly double with a target of €5.3M (+93.0%). The two exclusive distribution agreements established in 2025 deploy their full potential over a complete year. CDL Pharma (clinical research support activities) contributes €2.5M (growth of 289.7% on a comparable basis). Vela Diagnostics (commercial activities initiated in the second half of 2025) generates €1.6M with a growth of 457.2%. The software and solutions segment modestly progresses by 14.6% to €1.2M, supported by the resilience of the Nadis hospital software, which jumps by 117.2%.
In total, these three segments consolidate an unequal growth profile: while kits drive the increase, distribution agreements now constitute the second major contributor.
SectorDiagnostic et services de laboratoire›Diagnostic / labos d'analyse
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 5,4 millions d'euros
Quarterly revenue: 5,4 millions d'euros
Revenue growth: 90,1 %
EBITDA: 1,3 millions d'euros
EBITDA margin: 24,3 %
Net income: 1,3 millions d'euros
1 millions d'euros
Guidance from the release
The achievement of this objective remains dependent on: the timing of orders and deliveries; the ramp-up of the UltraGene range; the development of HIV activities; the contribution of Vela Diagnostics and CDL Pharma; supply conditions; regulatory deadlines
Risks mentioned
Timing of orders and deliveries remains uncertain and critical to achieving 2026 targets
Ramp-up execution of UltraGene range and HIV activities could face delays or operational challenges
Integration of Texcell France operations needs to successfully combine cultures and operations while maintaining financial discipline
Opportunities identified
Ramp-up of the UltraGene range (formerly Fast Track Diagnostics) with €1.582 million target for 2026
Expansion of HIV activities with €3.906 million annual target
Integration of Texcell France assets acquired in July 2026, adding 29 new employees and new virology and biosafety testing services
Outlook / guidance
Expected revenue: 13,8 millions d'euros
Management commentary: Sur la base des informations commerciales, opérationnelles et comptables disponibles à la date du présent communiqué, la Société anticipe désormais un chiffre d'affaires compris entre 13,5 M€ et 14,0 M€. Cette fourchette actualise l'objectif de 12,265 M€ publié le 1er juin 2026.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
